Comparison of methods to diagnose lymphoedema among breast cancer survivors: 6-month follow-up.
Identifieur interne : 003D46 ( PubMed/Curation ); précédent : 003D45; suivant : 003D47Comparison of methods to diagnose lymphoedema among breast cancer survivors: 6-month follow-up.
Auteurs : Sandi Hayes [Australie] ; Bruce Cornish ; Beth NewmanSource :
- Breast cancer research and treatment [ 0167-6806 ] ; 2005.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Adénocarcinome (), Adénocarcinome (anatomopathologie), Adénocarcinome (mortalité), Adénocarcinome mucineux (), Adénocarcinome mucineux (anatomopathologie), Adénocarcinome mucineux (mortalité), Carcinome canalaire du sein (), Carcinome canalaire du sein (anatomopathologie), Carcinome canalaire du sein (mortalité), Carcinome médullaire (), Carcinome médullaire (anatomopathologie), Carcinome médullaire (mortalité), Facteurs de risque, Femelle, Humains, Impédance électrique, Lymphadénectomie, Lymphoedème (diagnostic), Mastectomie partielle, Queensland, Récepteurs des oestrogènes (métabolisme), Récepteurs à la progestérone (métabolisme), Sujet âgé, Survivants, Tumeurs du sein (), Tumeurs du sein (anatomopathologie), Tumeurs du sein (mortalité), Études de suivi.
- MESH :
- anatomopathologie : Adénocarcinome, Adénocarcinome mucineux, Carcinome canalaire du sein, Carcinome médullaire, Tumeurs du sein.
- diagnostic : Lymphoedème.
- mortalité : Adénocarcinome, Adénocarcinome mucineux, Carcinome canalaire du sein, Carcinome médullaire, Tumeurs du sein.
- métabolisme : Récepteurs des oestrogènes, Récepteurs à la progestérone.
- Adulte d'âge moyen, Adénocarcinome, Adénocarcinome mucineux, Carcinome canalaire du sein, Carcinome médullaire, Facteurs de risque, Femelle, Humains, Impédance électrique, Lymphadénectomie, Mastectomie partielle, Queensland, Sujet âgé, Survivants, Tumeurs du sein, Études de suivi.
English descriptors
- KwdEn :
- Adenocarcinoma (mortality), Adenocarcinoma (pathology), Adenocarcinoma (therapy), Adenocarcinoma, Mucinous (mortality), Adenocarcinoma, Mucinous (pathology), Adenocarcinoma, Mucinous (therapy), Aged, Breast Neoplasms (mortality), Breast Neoplasms (pathology), Breast Neoplasms (therapy), Carcinoma, Ductal, Breast (mortality), Carcinoma, Ductal, Breast (pathology), Carcinoma, Ductal, Breast (therapy), Carcinoma, Medullary (mortality), Carcinoma, Medullary (pathology), Carcinoma, Medullary (therapy), Electric Impedance, Female, Follow-Up Studies, Humans, Lymph Node Excision, Lymphedema (diagnosis), Mastectomy, Segmental, Middle Aged, Queensland, Receptors, Estrogen (metabolism), Receptors, Progesterone (metabolism), Risk Factors, Survivors.
- MESH :
- chemical , metabolism : Receptors, Estrogen, Receptors, Progesterone.
- geographic : Queensland.
- diagnosis : Lymphedema.
- mortality : Adenocarcinoma, Adenocarcinoma, Mucinous, Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Medullary.
- pathology : Adenocarcinoma, Adenocarcinoma, Mucinous, Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Medullary.
- therapy : Adenocarcinoma, Adenocarcinoma, Mucinous, Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Medullary.
- Aged, Electric Impedance, Female, Follow-Up Studies, Humans, Lymph Node Excision, Mastectomy, Segmental, Middle Aged, Risk Factors, Survivors.
Abstract
One of the more problematic and dreaded complications of breast cancer is lymphoedema. Our objective was to determine the prevalence of lymphoedema 6-months following breast cancer treatment and to examine potential risk factors among a population-based sample of women residing in South-East Queensland (n = 176). Women were defined as having lymphoedema if the difference between the sum of arm circumferences (SOAC) of the treated and untreated sides was >5 cm (prevalence = 11.9%) or >10% (prevalence = 0.6%), their multi- frequency bioelectrical impedance (MFBIA) score was > or =3 standard deviations above the reference impedance score (prevalence = 11.4%), or they reported 'yes' when asked if arm swelling had been present in the previous 6 months (prevalence = 27.8%). Of those with lymphoedema defined by MFBIA, only 35% were detected using the SOAC method (difference > 5 cm), while 65% were identified via the self-report method (i.e., respective sensitivities). Specificities for SOAC (difference > 5 cm) and self-report were 88.5% and 76.9%, respectively. When examining associations between presence of lymphoedema and a range of characteristics, findings also varied depending on the method used to assess lymphoedema. Nevertheless, one of the more novel and significant findings was that being treated on the non-dominant, compared to dominant, side was associated with an 80% increased risk of having lymphoedema (MFBIA). Our work raises questions about the use of circumferences as the choice of measurement for lymphoedema in both research and clinical settings, and assesses MFBIA as a potential alternative.
DOI: 10.1007/s10549-004-2045-x
PubMed: 15754119
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003D46
Links to Exploration step
pubmed:15754119Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Comparison of methods to diagnose lymphoedema among breast cancer survivors: 6-month follow-up.</title><author><name sortKey="Hayes, Sandi" sort="Hayes, Sandi" uniqKey="Hayes S" first="Sandi" last="Hayes">Sandi Hayes</name><affiliation wicri:level="1"><nlm:affiliation>School of Public Health, Centre for Health Research, Brisbane, Australia. sc.hayes@qut.edu.au</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>School of Public Health, Centre for Health Research, Brisbane</wicri:regionArea></affiliation></author><author><name sortKey="Cornish, Bruce" sort="Cornish, Bruce" uniqKey="Cornish B" first="Bruce" last="Cornish">Bruce Cornish</name></author><author><name sortKey="Newman, Beth" sort="Newman, Beth" uniqKey="Newman B" first="Beth" last="Newman">Beth Newman</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:15754119</idno><idno type="pmid">15754119</idno><idno type="doi">10.1007/s10549-004-2045-x</idno><idno type="wicri:Area/PubMed/Corpus">003D46</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003D46</idno><idno type="wicri:Area/PubMed/Curation">003D46</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003D46</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Comparison of methods to diagnose lymphoedema among breast cancer survivors: 6-month follow-up.</title><author><name sortKey="Hayes, Sandi" sort="Hayes, Sandi" uniqKey="Hayes S" first="Sandi" last="Hayes">Sandi Hayes</name><affiliation wicri:level="1"><nlm:affiliation>School of Public Health, Centre for Health Research, Brisbane, Australia. sc.hayes@qut.edu.au</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>School of Public Health, Centre for Health Research, Brisbane</wicri:regionArea></affiliation></author><author><name sortKey="Cornish, Bruce" sort="Cornish, Bruce" uniqKey="Cornish B" first="Bruce" last="Cornish">Bruce Cornish</name></author><author><name sortKey="Newman, Beth" sort="Newman, Beth" uniqKey="Newman B" first="Beth" last="Newman">Beth Newman</name></author></analytic><series><title level="j">Breast cancer research and treatment</title><idno type="ISSN">0167-6806</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenocarcinoma (mortality)</term><term>Adenocarcinoma (pathology)</term><term>Adenocarcinoma (therapy)</term><term>Adenocarcinoma, Mucinous (mortality)</term><term>Adenocarcinoma, Mucinous (pathology)</term><term>Adenocarcinoma, Mucinous (therapy)</term><term>Aged</term><term>Breast Neoplasms (mortality)</term><term>Breast Neoplasms (pathology)</term><term>Breast Neoplasms (therapy)</term><term>Carcinoma, Ductal, Breast (mortality)</term><term>Carcinoma, Ductal, Breast (pathology)</term><term>Carcinoma, Ductal, Breast (therapy)</term><term>Carcinoma, Medullary (mortality)</term><term>Carcinoma, Medullary (pathology)</term><term>Carcinoma, Medullary (therapy)</term><term>Electric Impedance</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Lymph Node Excision</term><term>Lymphedema (diagnosis)</term><term>Mastectomy, Segmental</term><term>Middle Aged</term><term>Queensland</term><term>Receptors, Estrogen (metabolism)</term><term>Receptors, Progesterone (metabolism)</term><term>Risk Factors</term><term>Survivors</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Adénocarcinome ()</term><term>Adénocarcinome (anatomopathologie)</term><term>Adénocarcinome (mortalité)</term><term>Adénocarcinome mucineux ()</term><term>Adénocarcinome mucineux (anatomopathologie)</term><term>Adénocarcinome mucineux (mortalité)</term><term>Carcinome canalaire du sein ()</term><term>Carcinome canalaire du sein (anatomopathologie)</term><term>Carcinome canalaire du sein (mortalité)</term><term>Carcinome médullaire ()</term><term>Carcinome médullaire (anatomopathologie)</term><term>Carcinome médullaire (mortalité)</term><term>Facteurs de risque</term><term>Femelle</term><term>Humains</term><term>Impédance électrique</term><term>Lymphadénectomie</term><term>Lymphoedème (diagnostic)</term><term>Mastectomie partielle</term><term>Queensland</term><term>Récepteurs des oestrogènes (métabolisme)</term><term>Récepteurs à la progestérone (métabolisme)</term><term>Sujet âgé</term><term>Survivants</term><term>Tumeurs du sein ()</term><term>Tumeurs du sein (anatomopathologie)</term><term>Tumeurs du sein (mortalité)</term><term>Études de suivi</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Receptors, Estrogen</term><term>Receptors, Progesterone</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Queensland</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Adénocarcinome</term><term>Adénocarcinome mucineux</term><term>Carcinome canalaire du sein</term><term>Carcinome médullaire</term><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Lymphedema</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Lymphoedème</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Adenocarcinoma</term><term>Adenocarcinoma, Mucinous</term><term>Breast Neoplasms</term><term>Carcinoma, Ductal, Breast</term><term>Carcinoma, Medullary</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Adénocarcinome</term><term>Adénocarcinome mucineux</term><term>Carcinome canalaire du sein</term><term>Carcinome médullaire</term><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Récepteurs des oestrogènes</term><term>Récepteurs à la progestérone</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Adenocarcinoma</term><term>Adenocarcinoma, Mucinous</term><term>Breast Neoplasms</term><term>Carcinoma, Ductal, Breast</term><term>Carcinoma, Medullary</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Adenocarcinoma</term><term>Adenocarcinoma, Mucinous</term><term>Breast Neoplasms</term><term>Carcinoma, Ductal, Breast</term><term>Carcinoma, Medullary</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Electric Impedance</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Lymph Node Excision</term><term>Mastectomy, Segmental</term><term>Middle Aged</term><term>Risk Factors</term><term>Survivors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Adénocarcinome</term><term>Adénocarcinome mucineux</term><term>Carcinome canalaire du sein</term><term>Carcinome médullaire</term><term>Facteurs de risque</term><term>Femelle</term><term>Humains</term><term>Impédance électrique</term><term>Lymphadénectomie</term><term>Mastectomie partielle</term><term>Queensland</term><term>Sujet âgé</term><term>Survivants</term><term>Tumeurs du sein</term><term>Études de suivi</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">One of the more problematic and dreaded complications of breast cancer is lymphoedema. Our objective was to determine the prevalence of lymphoedema 6-months following breast cancer treatment and to examine potential risk factors among a population-based sample of women residing in South-East Queensland (n = 176). Women were defined as having lymphoedema if the difference between the sum of arm circumferences (SOAC) of the treated and untreated sides was >5 cm (prevalence = 11.9%) or >10% (prevalence = 0.6%), their multi- frequency bioelectrical impedance (MFBIA) score was > or =3 standard deviations above the reference impedance score (prevalence = 11.4%), or they reported 'yes' when asked if arm swelling had been present in the previous 6 months (prevalence = 27.8%). Of those with lymphoedema defined by MFBIA, only 35% were detected using the SOAC method (difference > 5 cm), while 65% were identified via the self-report method (i.e., respective sensitivities). Specificities for SOAC (difference > 5 cm) and self-report were 88.5% and 76.9%, respectively. When examining associations between presence of lymphoedema and a range of characteristics, findings also varied depending on the method used to assess lymphoedema. Nevertheless, one of the more novel and significant findings was that being treated on the non-dominant, compared to dominant, side was associated with an 80% increased risk of having lymphoedema (MFBIA). Our work raises questions about the use of circumferences as the choice of measurement for lymphoedema in both research and clinical settings, and assesses MFBIA as a potential alternative.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15754119</PMID><DateCreated><Year>2005</Year><Month>03</Month><Day>08</Day></DateCreated><DateCompleted><Year>2005</Year><Month>05</Month><Day>19</Day></DateCompleted><DateRevised><Year>2015</Year><Month>08</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0167-6806</ISSN><JournalIssue CitedMedium="Print"><Volume>89</Volume><Issue>3</Issue><PubDate><Year>2005</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Breast cancer research and treatment</Title><ISOAbbreviation>Breast Cancer Res. Treat.</ISOAbbreviation></Journal><ArticleTitle>Comparison of methods to diagnose lymphoedema among breast cancer survivors: 6-month follow-up.</ArticleTitle><Pagination><MedlinePgn>221-6</MedlinePgn></Pagination><Abstract><AbstractText>One of the more problematic and dreaded complications of breast cancer is lymphoedema. Our objective was to determine the prevalence of lymphoedema 6-months following breast cancer treatment and to examine potential risk factors among a population-based sample of women residing in South-East Queensland (n = 176). Women were defined as having lymphoedema if the difference between the sum of arm circumferences (SOAC) of the treated and untreated sides was >5 cm (prevalence = 11.9%) or >10% (prevalence = 0.6%), their multi- frequency bioelectrical impedance (MFBIA) score was > or =3 standard deviations above the reference impedance score (prevalence = 11.4%), or they reported 'yes' when asked if arm swelling had been present in the previous 6 months (prevalence = 27.8%). Of those with lymphoedema defined by MFBIA, only 35% were detected using the SOAC method (difference > 5 cm), while 65% were identified via the self-report method (i.e., respective sensitivities). Specificities for SOAC (difference > 5 cm) and self-report were 88.5% and 76.9%, respectively. When examining associations between presence of lymphoedema and a range of characteristics, findings also varied depending on the method used to assess lymphoedema. Nevertheless, one of the more novel and significant findings was that being treated on the non-dominant, compared to dominant, side was associated with an 80% increased risk of having lymphoedema (MFBIA). Our work raises questions about the use of circumferences as the choice of measurement for lymphoedema in both research and clinical settings, and assesses MFBIA as a potential alternative.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hayes</LastName><ForeName>Sandi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Public Health, Centre for Health Research, Brisbane, Australia. sc.hayes@qut.edu.au</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cornish</LastName><ForeName>Bruce</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Newman</LastName><ForeName>Beth</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Breast Cancer Res Treat</MedlineTA><NlmUniqueID>8111104</NlmUniqueID><ISSNLinking>0167-6806</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011960">Receptors, Estrogen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011980">Receptors, Progesterone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Breast Cancer Res Treat. 2015 Jul;152(1):227-8</RefSource><PMID Version="1">25975953</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000230" MajorTopicYN="N">Adenocarcinoma</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002288" MajorTopicYN="N">Adenocarcinoma, Mucinous</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018270" MajorTopicYN="N">Carcinoma, Ductal, Breast</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018276" MajorTopicYN="N">Carcinoma, Medullary</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017097" MajorTopicYN="N">Electric Impedance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008197" MajorTopicYN="N">Lymph Node Excision</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015412" MajorTopicYN="N">Mastectomy, Segmental</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011793" MajorTopicYN="N" Type="Geographic">Queensland</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011960" MajorTopicYN="N">Receptors, Estrogen</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011980" MajorTopicYN="N">Receptors, Progesterone</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017741" MajorTopicYN="Y">Survivors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>3</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>5</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>3</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15754119</ArticleId><ArticleId IdType="doi">10.1007/s10549-004-2045-x</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003D46 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 003D46 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:15754119
|texte= Comparison of methods to diagnose lymphoedema among breast cancer survivors: 6-month follow-up.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:15754119" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |